Yang Kaige, Wang Weiwei, Wang Yan, Yan Chao
School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, China.
Se Pu. 2021 Nov;39(11):1191-1202. doi: 10.3724/SP.J.1123.2021.04009.
Exosomes are extracellular vesicles with a diameter in the range of 50-200 nm and a double-layer lipid membrane structure that are released by various types of cells under normal or abnormal physiological conditions. At present, according to their extensive biological functions, exosomes have been used in a wide range of research fields and applications, including as potential biomarkers and drug delivery vehicles. Intrahepatic cholangiocarcinoma is a malignant tumor of the biliary epithelium with the characteristics of cholangiocellular differentiation, which accounts for 10%-15% of all types of primary liver cancer. Intrahepatic cholangiocarcinoma has no obvious clinical symptoms in the early stages, which results in a low survival rate. Imaging equipment dependent diagnostic methods and currently commonly used diagnostic markers with low sensitivity/specificity have necessitated the development of new specific markers for intrahepatic cholangiocarcinoma. In this study, exosomes were isolated from serum using a commercial kit and characterized through nanoparticle tracking analysis, Western blotting analysis, and transmission electron microscopic analysis to prove the successful isolation of exosomes. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) showed that the protein profiles of the serum and serum exosome samples were significantly different. In particular, some high-abundance proteins in the serum samples were significantly reduced or disappeared in the serum exosome sample. Meanwhile, some protein bands (which may belong to exosomes) that did not appear in the serum samples appeared in the serum exosome samples, leading to the conduciveness of subsequent mass spectrometry analysis. The serum and serum exosome samples of the healthy control and intrahepatic cholangiocarcinoma groups were analyzed by liquid chromatography-mass spectrometry for label-free quantitative proteomics. In total, 547 proteins were identified in the serum exosome samples, of which 341 (more than 60%) could be found in the exosomal protein database. In addition, 271 and 430 credible proteins were screened from the serum and serum exosome samples for multi-dimensional statistical analysis and differential protein discovery. Unsupervised principal component analysis and supervised orthogonal partial least squares discriminant analysis based on the quantitative proteome of the serum and serum exosome samples could distinguish the healthy control and intrahepatic cholangiocarcinoma groups well, which illustrates that the two types of samples both have potential in the diagnosis of intrahepatic cholangiocarcinoma. There were 15 upregulated and 8 downregulated proteins screened in the intrahepatic cholangiocarcinoma group compared to the healthy control group based on the serum samples, while 33 upregulated and 18 downregulated proteins were screened in the intrahepatic cholangiocarcinoma group compared to the healthy control group based on the serum exosome samples, and only four of the differential proteins screened based on the two types of samples were duplicates. At the same time, 35 of the 51 differentially expressed proteins screened based on serum exosome samples belonged to the exosomal protein database. Finally, biological information analysis was performed according to these differential proteins. The molecular functions, biological processes, and signal pathways enriched by these differential proteins mainly involved the innate immune responses, inflammatory responses, and blood coagulation. This study provides a reference value for potential biomarker discovery and exploration of the process of occurrence, development, and metastasis of intrahepatic cholangiocarcinoma. Moreover, compared with proteomic analysis based on serum samples, proteomic analysis based on serum exosome samples can be used to identify more differential proteins and biological information, and although these differential proteins and biological information may show big differences, the specificity and sensitivity of exosome-based diagnosis and the superiority of exosomes as samples for proteomic analysis has proven the application value of exosomes.
外泌体是直径在50-200nm范围内的细胞外囊泡,具有双层脂质膜结构,在正常或异常生理条件下由各种类型的细胞释放。目前,基于其广泛的生物学功能,外泌体已被应用于广泛的研究领域和应用中,包括作为潜在的生物标志物和药物递送载体。肝内胆管癌是一种具有胆管细胞分化特征的胆管上皮恶性肿瘤,占所有原发性肝癌类型的10%-15%。肝内胆管癌在早期没有明显的临床症状,导致生存率较低。依赖成像设备的诊断方法以及目前常用的诊断标志物敏感性/特异性较低,因此需要开发新的肝内胆管癌特异性标志物。在本研究中,使用商业试剂盒从血清中分离出外泌体,并通过纳米颗粒跟踪分析、蛋白质印迹分析和透射电子显微镜分析对其进行表征,以证明外泌体的成功分离。十二烷基硫酸钠-聚丙烯酰胺凝胶电泳(SDS-PAGE)显示,血清和血清外泌体样品的蛋白质谱有显著差异。特别是,血清样品中的一些高丰度蛋白质在血清外泌体样品中显著减少或消失。同时,血清样品中未出现的一些蛋白条带(可能属于外泌体)出现在血清外泌体样品中,有利于后续的质谱分析。通过液相色谱-质谱联用对健康对照组和肝内胆管癌组的血清和血清外泌体样品进行无标记定量蛋白质组学分析。血清外泌体样品中共鉴定出547种蛋白质,其中341种(超过60%)可在细胞外囊泡蛋白质数据库中找到。此外,从血清和血清外泌体样品中筛选出271种和430种可靠蛋白质进行多维统计分析和差异蛋白质发现。基于血清和血清外泌体样品的定量蛋白质组进行的无监督主成分分析和有监督的正交偏最小二乘判别分析能够很好地区分健康对照组和肝内胆管癌组,这表明这两种类型的样品在肝内胆管癌诊断中都具有潜力。基于血清样品,与健康对照组相比,肝内胆管癌组筛选出15种上调蛋白和8种下调蛋白;基于血清外泌体样品,与健康对照组相比,肝内胆管癌组筛选出33种上调蛋白和18种下调蛋白,基于两种类型样品筛选出的差异蛋白中只有4种是重复的。同时,基于血清外泌体样品筛选出的51种差异表达蛋白中有35种属于细胞外囊泡蛋白质数据库。最后,根据这些差异蛋白进行生物信息分析。这些差异蛋白富集的分子功能、生物学过程和信号通路主要涉及先天免疫反应、炎症反应和凝血。本研究为肝内胆管癌潜在生物标志物的发现以及其发生、发展和转移过程的探索提供了参考价值。此外,与基于血清样品的蛋白质组分析相比,基于血清外泌体样品的蛋白质组分析能够鉴定出更多的差异蛋白和生物信息,尽管这些差异蛋白和生物信息可能存在很大差异,但外泌体诊断的特异性和敏感性以及外泌体作为蛋白质组分析样品的优越性已证明了外泌体的应用价值。